For example, CDCA3 was overexpressed in stage IV cancer (log2(FC) = 1.2, FDR = 6.39e-07) and overexpression of CDCA3 has been reported to be associated with oral cancer progression [49] and prostate cancer [50], which suggests that CDCA3 also plays an important role in KIRC progression and serves as a potential therapeutic target for KIRC. This evidence concerns the gene CDCA3 and Familial prostate cancer.